GLP-1受容体アゴニストおよびグルカゴン受容体アンタゴニストの双方として作用するペプチドおよびそれらの薬剤学的使用方法 - Bayer Pharmaceuticals Corporates Corporation

Title:

GLP-1受容体アゴニストおよびグルカゴン受容体アンタゴニストの双方として作用するペプチドおよびそれらの薬剤学的使用方法

Document Type and Number:

Japanese Patent JP2005508639

Kind Code:

A

Abstract:

The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.

More Like This:

JP2022500009	Compositions and Methods for Enhancing Donor Oligonucleotide-Based Gene Editing
WO/2022/211129	ANTISENSE OLIGONUCLEOTIDE DERIVATIVE FOR ATN1
WO/2006/122464	AN OLIGONUCLEOTIDE OR ITS FUNCTIONAL HOMOLOGUE, A COMPOSITION COMPRISING THE SAME AND A METHOD FOR TREATING B CELL NEOPLASM

Inventors:

Bread clark
Wellin, The Ames
Claremont, Kevin Bee

Application Number:

JP2003542556A

Publication Date:

April 07, 2005

Filing Date:

October 04, 2002

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Bayer Pharmaceuticals Corporates Corporation

International Classes:

A61K31/7088; A61K38/00; A61K38/22; A61K48/00; A61P3/00; A61P3/04; A61P3/08; A61P3/10; A61P43/00; C07K14/47; C07K14/575; C07K14/605; C07K14/745; C07K16/00; C07K16/18; C12N1/15; C12N15/09; C12N1/19; C12N1/21; C12N5/10; C12N15/00; C12P21/02; (IPC1-7): C12N15/09; A61K31/7088; A61K38/00; A61K48/00; A61P3/00; A61P3/04; A61P3/10; A61P43/00; C07K14/47; C07K14/745; C07K16/18; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/02

Attorney, Agent or Firm:

Heikichi Odashima

Previous Patent: ７１１８、ヒトアルギニンＮ−メチルトランスフェラーゼファミリーメン�...

Next Patent: ２型サイトカインレセプターおよびそれをコードする核酸